Pediatric Pulmonary Hypertension Registry: Real-world Outcomes and Epidemiology

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

INSPIRE-PH is a multicenter, observational real-world registry that systematically collects longitudinal clinical and outcome data on children and adolescents diagnosed with pulmonary hypertension. Enrolled patients receive standard care from their treating physicians and no study-mandated interventions are imposed. The registry captures diagnostic, hemodynamic, treatment, and follow-up information to characterize disease course, treatment patterns, and prognosis over time. The cohort began prospectively in 2006 and cases have been reclassified according to contemporary World Symposium on Pulmonary Hypertension criteria to enable longitudinal comparisons.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children and adolescents aged \<18 years at diagnosis
* Diagnosed pulmonary hypertension (PH) according to the prevailing diagnostic criteria at the time of enrollment
* Enrollment in the registry at participating centers
* Provision of informed consent by patients and/or legal guardians
* Availability for longitudinal follow-up

Exclusion Criteria:

* Inability to confirm PH diagnosis due to insufficient clinical or hemodynamic data
* Refusal or inability to provide informed consent

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Jie-Xin Zhang, Dr.
• Email: jx_zhang_vip@163.com
• Phone: +86-18629534652

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD

  This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.

  Recruiting at 2 sites Early Phase 1 Valley Health System · Paramus, New Jersey and 1 other locations · NCT07837830

• Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension

  This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.

  Recruiting Hospital de Clinicas de Porto Alegre · Porto Alegre · NCT07822997

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Pulmonary Artery Denervation for Pulmonary Hypertension After M-TEER

  This study tests whether PADN can help people with pulmonary hypertension after M-TEER compared with standard medical therapy.

  Recruiting Early Phase 1 Xiamen Cardiovascular Hospital, Xiamen University · Xiamen, Fujian · NCT07662655

• Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

  This study tests how to identify people with pulmonary hypertension who are at risk of a sudden, life-threatening crisis.

  Recruiting at 4 sites Peking Union Medical College Hospital · Guangzhou, Guangdong and 3 other locations · NCT07653958

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.